Qiagen Grants Performance Stock Units to Managing Board Member

The latest announcement is out from Qiagen ( (QGEN) ).

Qiagen has disclosed a managers’ transaction involving Roland Sackers, a member of the company’s managing body, in line with European market abuse regulations. The notification reports the grant of 70,305 Performance Stock Units linked to Qiagen shares to Sackers on February 27, 2026, outside a trading venue, under the company’s share-based compensation program.

The award of Performance Stock Units highlights Qiagen’s continued use of equity-linked incentives to align management interests with those of shareholders. Such grants can reinforce long-term commitment of key executives and may modestly influence future share dilution, while signaling confidence in Qiagen’s strategic direction and performance targets.

The most recent analyst rating on (QGEN) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.

More about Qiagen

Qiagen N.V. is a Netherlands-based life sciences company that develops and supplies sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its shares are listed on multiple European exchanges as well as the NYSE and Swiss markets, reflecting its position as an internationally traded diagnostics and biotech player.

Average Trading Volume: 2,173,009

Technical Sentiment Signal: Strong Buy

Current Market Cap: $10.1B

For a thorough assessment of QGEN stock, go to TipRanks’ Stock Analysis page.